Analysis Clinical trials

XORTX completes gout trial supply; Health Canada and FDA filings are next

Finished clinical supply for the XRX-OXY-102 oxypurinol study removes one common bottleneck, but the record leaves open the filing timing, trial design and funding.

VigiEye editorial · Tue 17 Nov 2026

What happened

XORTX Therapeutics says manufacturing and packaging of the drug supply for its oxypurinol tablet gout study, XRX-OXY-102, is finished. The company describes the work as completed ahead of planned filings with Health Canada and the FDA. The product is referred to as XORLO.

The disclosure comes from a company exhibit filed with the SEC. The record does not say when the filings will be made or what type they will be. It also gives no batch size, no manufacturing site, no enrolment target and no trial start date.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →